Beam Therapeutics (BEAM) Competitors $25.96 +0.17 (+0.64%) As of 10:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BEAM vs. CRSP, DNLI, EDIT, NTLA, TWST, VCYT, QGEN, BBIO, ELAN, and VRNAShould you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Twist Bioscience (TWST), Veracyte (VCYT), Qiagen (QGEN), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "medical" sector. Beam Therapeutics vs. Its Competitors CRISPR Therapeutics Denali Therapeutics Editas Medicine Intellia Therapeutics Twist Bioscience Veracyte Qiagen BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation. Which has more volatility and risk, BEAM or CRSP? Beam Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Is BEAM or CRSP more profitable? Beam Therapeutics has a net margin of -661.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-661.31% -43.15% -31.06% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Which has better earnings & valuation, BEAM or CRSP? CRISPR Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M41.34-$376.74M-$4.50-5.77CRISPR Therapeutics$37.31M165.95-$366.25M-$5.43-12.54 Do insiders & institutionals believe in BEAM or CRSP? 99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.5% of Beam Therapeutics shares are held by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend BEAM or CRSP? Beam Therapeutics presently has a consensus price target of $45.92, indicating a potential upside of 76.91%. CRISPR Therapeutics has a consensus price target of $72.59, indicating a potential upside of 6.63%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 2.94CRISPR Therapeutics 2 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.42 Does the media prefer BEAM or CRSP? In the previous week, CRISPR Therapeutics had 24 more articles in the media than Beam Therapeutics. MarketBeat recorded 31 mentions for CRISPR Therapeutics and 7 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.61 beat Beam Therapeutics' score of 0.58 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBeam Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks. Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAM vs. The Competition Export to ExcelMetricBeam TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.63B$3.42B$6.10B$10.49BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-5.7723.0484.6327.17Price / Sales41.34484.44608.51132.45Price / CashN/A46.9737.8662.13Price / Book2.9310.5112.356.62Net Income-$376.74M-$52.47M$3.33B$276.88M7 Day Performance-1.39%3.06%2.11%1.49%1 Month Performance15.61%15.52%9.40%4.79%1 Year Performance6.59%13.77%73.46%36.32% Beam Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEAMBeam Therapeutics3.4357 of 5 stars$25.96+0.6%$45.92+76.9%-3.4%$2.63B$63.52M-5.77510CRSPCRISPR Therapeutics2.2415 of 5 stars$70.19+3.6%$71.50+1.9%+39.7%$6.38B$37.31M-12.93460Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionGap UpDNLIDenali Therapeutics4.1674 of 5 stars$15.22-1.3%$33.50+120.1%-39.6%$2.23B$330.53M-5.44430News CoverageAnalyst RevisionEDITEditas Medicine4.1848 of 5 stars$3.80-3.1%$5.10+34.2%+14.8%$341.70M$32.31M-1.33230Gap DownNTLAIntellia Therapeutics4.171 of 5 stars$20.54+2.9%$27.95+36.1%+21.0%$2.20B$57.88M-4.38600Gap DownTWSTTwist Bioscience3.8478 of 5 stars$31.85+2.5%$48.90+53.5%-31.8%$1.92B$312.97M-21.97990Analyst RevisionVCYTVeracyte3.6891 of 5 stars$36.04+0.1%$40.90+13.5%+3.1%$2.84B$445.76M109.22790News CoverageQGENQiagen4.1228 of 5 stars$46.99+0.4%$49.40+5.1%+14.5%$10.45B$1.98B27.765,765BBIOBridgeBio Pharma4.4949 of 5 stars$54.61+3.3%$63.94+17.1%+108.9%$10.44B$221.90M-13.35400Positive NewsAnalyst RevisionELANElanco Animal Health2.5478 of 5 stars$20.68+0.2%$18.33-11.3%+54.6%$10.27B$4.44B24.059,000Analyst RevisionVRNAVerona Pharma PLC American Depositary Share1.536 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive News Related Companies and Tools Related Companies CRSP Alternatives DNLI Alternatives EDIT Alternatives NTLA Alternatives TWST Alternatives VCYT Alternatives QGEN Alternatives BBIO Alternatives ELAN Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BEAM) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
